Nivolumab or Pembrolizumab Combos in Advanced Kidney Cancer?

Immunotherapy combinations based on nivolumab entail lower costs for grade 3/4 adverse events than those using pembrolizumab, a finding that could inform treatment decisions.
Medscape Medical News

source https://www.medscape.com/viewarticle/986820?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?